JP2010540422A - チエノピリミジン化合物類 - Google Patents

チエノピリミジン化合物類 Download PDF

Info

Publication number
JP2010540422A
JP2010540422A JP2010525422A JP2010525422A JP2010540422A JP 2010540422 A JP2010540422 A JP 2010540422A JP 2010525422 A JP2010525422 A JP 2010525422A JP 2010525422 A JP2010525422 A JP 2010525422A JP 2010540422 A JP2010540422 A JP 2010540422A
Authority
JP
Japan
Prior art keywords
optionally substituted
compound according
alkyl
methyl
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010525422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540422A5 (enExample
Inventor
ジョーダン，アラン
ベッドフォード，サイモン
ブルクハルト，クレンケ
ユール，イアン
プーラネック，カリーヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of JP2010540422A publication Critical patent/JP2010540422A/ja
Publication of JP2010540422A5 publication Critical patent/JP2010540422A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010525422A 2007-09-21 2008-09-19 チエノピリミジン化合物類 Pending JP2010540422A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0718434A GB0718434D0 (en) 2007-09-21 2007-09-21 New chemical compounds
PCT/GB2008/003173 WO2009037463A1 (en) 2007-09-21 2008-09-19 Thienopyrimidine compounds

Publications (2)

Publication Number Publication Date
JP2010540422A true JP2010540422A (ja) 2010-12-24
JP2010540422A5 JP2010540422A5 (enExample) 2011-11-04

Family

ID=38670289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010525422A Pending JP2010540422A (ja) 2007-09-21 2008-09-19 チエノピリミジン化合物類

Country Status (5)

Country Link
US (5) US9120807B2 (enExample)
EP (1) EP2205607A1 (enExample)
JP (1) JP2010540422A (enExample)
GB (1) GB0718434D0 (enExample)
WO (1) WO2009037463A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10793636B2 (en) 2016-07-11 2020-10-06 Corvus Pharmaceuticals, Inc. Anti-CD73 antibodies
EP3675856A4 (en) 2017-08-31 2021-04-14 Corvus Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR MODULATING THE A2B ADENOSINE RECEPTOR AND A2A ADENOSINE RECEPTOR
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503504A (ja) * 1999-07-01 2003-01-28 バーナリス リサーチ リミテッド Ａ２ａレセプターアンタゴニストとしてのチエノおよびフロピリミジン誘導体
JP2005525305A (ja) * 2001-12-20 2005-08-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロピリミジンＡ２ｂ選択的アンタゴニスト化合物、それらの合成、及び使用
JP2007509947A (ja) * 2003-10-31 2007-04-19 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン受容体アンタゴニスト
WO2007103776A2 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
WO2003063800A2 (en) 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503504A (ja) * 1999-07-01 2003-01-28 バーナリス リサーチ リミテッド Ａ２ａレセプターアンタゴニストとしてのチエノおよびフロピリミジン誘導体
JP2005525305A (ja) * 2001-12-20 2005-08-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロピリミジンＡ２ｂ選択的アンタゴニスト化合物、それらの合成、及び使用
JP2007509947A (ja) * 2003-10-31 2007-04-19 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン受容体アンタゴニスト
WO2007103776A2 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists

Also Published As

Publication number Publication date
EP2205607A1 (en) 2010-07-14
US9920066B2 (en) 2018-03-20
US20200140455A1 (en) 2020-05-07
US9610290B2 (en) 2017-04-04
US20150342953A1 (en) 2015-12-03
US20170291907A1 (en) 2017-10-12
US11028097B2 (en) 2021-06-08
WO2009037463A1 (en) 2009-03-26
US20180162872A1 (en) 2018-06-14
US20110118284A1 (en) 2011-05-19
GB0718434D0 (en) 2007-10-31
US9120807B2 (en) 2015-09-01
US10556911B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
JP2010540424A (ja) チエノピリミジン化合物類および組成物
JP6035423B2 (ja) 新規な縮合ピリミジン化合物又はその塩
US11028097B2 (en) Thienopyrimidine compounds
KR20210150491A (ko) 포스파티딜이노시톨 3-키나제 저해제
JP2011529918A (ja) Ｊａｋ３阻害剤としてのピペリジン誘導体
WO2019134539A1 (zh) 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
JP7532353B2 (ja) Ｈ４アンタゴニスト化合物としてのピラゾール誘導体
CN114585359A (zh) 用于治疗pd-l1疾病的杂芳基联苯酰胺
CN113754679B (zh) 取代的嘧啶二酮类化合物及其用途
EP2590981A1 (en) Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
JP2025160175A (ja) Ｃｄ３８阻害剤としてのキノリン及びアザキノリン
US20100305143A1 (en) Pyrrolopyrimidine compounds
CN103313707A (zh) 二苯基-胺衍生物的用途、合成方法及药物组合物
WO2025139240A1 (zh) Parp7抑制剂及其用途
US20210009612A1 (en) Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof
TWI652265B (zh) 氮雜吲哚衍生物
CN112851583B (zh) 新型苯并氮杂䓬类化合物、组合物及其用途
WO2011078226A1 (ja) 三環系化合物
CN116438181A (zh) 磺酰胺基取代的杂芳基嘧啶二酮类化合物及其用途
JPWO2003020723A1 (ja) ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
CN112209933B (zh) 含有4-氮杂螺庚烷的btk抑制剂
JP7671307B2 (ja) Ｈ４アンタゴニスト化合物
WO2023083373A1 (zh) 作为Src抑制剂的化合物
JP2000239277A (ja) イミダゾキナゾリン誘導体
HK40014729B (zh) 吗啡喃衍生物的在阿片δ受体激动剂相关疾病的治疗中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130521

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131105